The INSEMA trial: redefining axillary surgery in early breast cancer
DOI:
https://doi.org/10.18203/2349-2902.isj20260485Keywords:
INSEMA, Omittinh axillary dissection, Axillary surgeryAbstract
We read with great interest the INSEMA (Intergroup-Sentinel-Mamma) trial published in the New England journal of medicine in 2025, which evaluates the oncologic safety of omitting sentinel lymph node biopsy (SLNB) in clinically node-negative early breast cancer. This landmark study represents a major step toward surgical de-escalation; however, important limitations must be carefully considered before widespread implementation, particularly in resource-limited settings.
Metrics
References
Toralf R, Angrit S, Kristina V, Thorsten K, Jörg H, Silke P, et al. Axillary Surgery in Breast Cancer-Primary Results of the INSEMA Trial. N Engl J Med. 2025;392(11):1051-64. DOI: https://doi.org/10.1056/NEJMoa2412063
Reznik J, Cicchetti MG, Degaspe B, Fitzgerald TJ. Analysis of axillary coverage during tangential radiation therapy to the breast. Int J Radiation Oncol Biol Physics. 2005;61(1):163-8. DOI: https://doi.org/10.1016/j.ijrobp.2004.04.065
McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer: Targets Therapy. 2017;9:393-400. DOI: https://doi.org/10.2147/BCTT.S109847
Downloads
Published
How to Cite
Issue
Section
